Intentional weight loss and dose reductions of anti-diabetic medications - a retrospective cohort study

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Kumar, Anita Ashok ^a   Palamaner Subash Shantha, Ghanshyam ^a   Kahan, Scott ^a,b,c   Samson, Rohit Joshua ^c   da Boddu, Nelsonvid ^c   Cheskin, Lawrence Jay ^a,c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; INSULIN; METFORMIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; PYRAZINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; INTENTIONAL WEIGHT LOSS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RETROSPECTIVE STUDY; WEIGHT REDUCTION; AGED; DIABETES MELLITUS; DRUG EFFECT; MIDDLE AGED; REGRESSION ANALYSIS;

ADULT; AGED; BODY MASS INDEX; COHORT STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; PYRAZINES; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SULFONYLUREA COMPOUNDS; TRIAZOLES; WEIGHT LOSS;

EID: 84863282465     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032395     Document Type: Article

References (23)

1. Flegal KM, Carroll MD, Ogden CL, Curtin LR, (2010) Prevalence and trends in obesity among US adults, 1999-2008. JAMA 303 (3): 235-41.
2. Nguyen NT, Magno CP, Lane KT, Hinojosa MW, Lane JS, (2008) Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity: findings from the National Health and Nutrition Examination Survey, 1999 to 2004. J Am Coll Surg 207 (6): 928-934.
3. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, et al. (2003) Prevalence of obesity, diabetes, and obesity- related health risk factors, 2001. JAMA 289 (1): 76-79.
4. Ahamed A, Shantha GP, Agarwal G, Senthil N, Paunikar N, et al. (2008) Prevalence of microvascular complications in metabolic syndrome in comparison to type 2 diabetes mellitus. J Indian Med Assoc 106 (9): 583-4, 586, 588.
5. Flegal KM, Graubard BI, Williamson DF, Gail MH, (2007) Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA 298 (17): 2028-2037.
6. Colditz G, (1999) Economic costs of obesity and inactivity. Med Sci Sports Exerc 31 (suppl): S663-S667.
7. American Diabetes Association (1998) Economic consequences of diabetes mellitus in the US in 1997. Diabetes Care 21: 296-309.
8. Pi-Sunyer X, Blackburn G, Brancati FL, Bray GA, Bright R, et al. (2007) Look AHEAD Research Group. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care 30 (6): 1374-1383.
9. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, et al. (2002) Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (6): 393-403.
10. Jeffrey SF, Eleftheria MF, Obesity: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, (2005) Harrison's Principles of Internal Medicine, Vol 1, 16th edition New York Mc Graw Hill Inc pp. 422-423.
11. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of high Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA (2001) 285: 2486-97.
12. WHO Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. WHO Technical Report Series 854 1995 Geneva World Health Organization.
13. Greenberg RS, Daniels SR, Dana Flanders W, et al. Diagnostic testing. In: Greenberg RS, editors. Medical Epidemiology 2005 New York McGraw-Hill.
14. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, et al. (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344: 1343-50.
15. Lindström J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, et al. (2006) Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 368 (9548): 1673-9.
16. Redmon JB, Bertoni AG, Connelly S, Feeney PA, Glasser SP, et al. (2010) Effect of the look AHEAD study intervention on medication use and related cost to treat cardiovascular disease risk factors in individuals with type 2 diabetes. Diabetes Care 33 (6): 1153-8.
17. Dixon JB, O'Brien PE, Playfair J, Chapman L, Schachter LM, et al. (2008) Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 299 (3): 316-23.
18. Ito H, Ishida H, Takeuchi Y, Antoku S, Abe M, et al. (2010) Long-term effect of metformin on blood glucose control in non-obese patients with type 2 diabetes mellitus. Nutr Metab (Lond) 7: 83.
19. Sjostrom L, Lindroos AK, Peltonen M, Torgerson J, et al. (2004) Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 351: 2683-2693.
20. Dixon JB, O'Brien PE, Playfair J, Chapman L, et al. (2008) Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 299: 316-323.
21. Dixon JB, (2009) Obesity and diabetes: the impact of bariatric surgery on type-2 diabetes. World J Surg 33 (10): 2014-21.
22. Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, et al. (2011) Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med 154 (8): 554-9.
23. Peyrot M, Rubin RR, Chen X, Frias JP, (2011) Associations between improved glucose control and patient-reported outcomes after initiation of insulin pump therapy in patients with type 2 diabetes mellitus. Diabetes Technol Ther 13 (4): 471-6.